SUMMARY
Notch receptors and ligands mediate heterotypic cell signaling that is required for normal vascular development. Dysregulation of select Notch receptors in mouse vascular smooth muscle (VSM) and in genetic human syndromes causes functional impairment in some regional circulations the mechanistic basis of which is undefined. In this study, we used a dominant negative Mastermind (DNMAML1) to block signaling through all Notch receptors specifically in VSM to more broadly test a functional role for this pathway in vivo. Mutant, DNMAML1-expressing, mice exhibited blunted blood pressure responses to vasoconstrictors and their aortic, femoral and mesenteric arteries had reduced contractile responses to agonists and depolarization in vitro. The mutant arteries had significant and specific reduction in the expression and activity of myosin light chain kinase (MLCK), a primary regulator of VSM force production. Conversely, activated Notch signaling in VSM cells induced endogenous MLCK transcript levels. We identified MLCK as a direct target of activated Notch receptor as demonstrated by an evolutionarily conserved Notch responsive element within the MLCK promoter, which binds the Notch receptor complex and is required for transcriptional activity. We conclude that Notch signaling through the transcriptional control of key regulatory proteins is required for contractile responses of mature VSM. Genetic or pharmacological manipulation of Notch signaling is a potential strategy for modulating arterial function in human disease.
________________________________________
The Notch signaling cascade provides critical functions during vertebrate vascular development and post-natal maturation. Notch receptors (Notch1-4) are single-pass transmembrane proteins activated by interactions with ligands (Delta and Jagged) present on neighboring cell membranes, resulting in a gamma secretase-dependent receptor cleavage and translocation of the Notch intracellular domain (NICD) into the nucleus. In canonical Notch signaling, NICD partners with the transcriptional activator, Mastermind (MAM), and a DNA binding protein, CSL [CBF1/Su(H)/Lag2 protein; a.k.a. RBP-Jκ], targeting the complex to gene promoters containing the consensus motif, GTGGGAA (1) (2) (3) .
In vascular wall cells, HRT/HEY basic helix-loop-helix genes have been identified as important targets and functional mediators of Notch receptor activation, particularly during developmental angiogenesis and post-natal vascular injury responses (4, 5) .
In humans, mutations in the Notch3 receptor are linked to CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) syndrome, which features a progressive non-atheromatous arteriopathy in brain arterioles punctuated by vessel stenoses, cerebral ischemia and infarction (6) . Modeling of this syndrome and that of deletion of the Notch3 receptor in mice further uncovered impaired myogenic responses in caudal, cerebral and renal arteries (7) (8) (9) (10) (11) . Investigations in these animals revealed altered contractile gene content as well as reduced levels of phosphorylated myosin light chain (MLC) attributed to defective RhoA/Rho kinase signaling (7, 8) . However, vascular dysfunction was not detected in most systemic arterial and resistance vasculature, suggesting a regional and complex influence through which impaired Notch3 signaling affected vascular smooth muscle myogenic responses. Importantly, smooth muscle Notch signaling was not abolished in these animal models due to expression of additional Notch receptors and pathway components.
Force of contraction of VSM is determined by the opposing activities of MLCK and MLC phosphatase (MP), and MLCK is required for both physiological and pathological blood pressure (12, 13) . MLCK expression is transcriptionally regulated by serum response factor (SRF) and its co-activator, myocardin (14, 15) . Functionally, Ca 2+ /calmodulin-dependent MLCK activity phosphorylates MLC (p-MLC) and activates the myosin ATPase causing contraction, while phosphate removal by MP inactivates myosin causing relaxation (16, 17) .
Given the unique vascular myogenic deficits associated with dysregulation of a single Notch receptor (Notch3), the current study was designed to more broadly examine vascular function and identify critical targets of Notch signaling by disrupting the canonical pathway in VSM.
We hypothesized that Notch signals modulate the transcription of key regulatory contractile proteins and tested this by examining expression and function in a mouse model expressing a dominant-negative Mastermind-Like (DNMAML1) protein to inhibit (CSL-dependent) Notch signaling targeted specifically to smooth muscle with the SM22α-Cre promoter (18) . This model suppresses canonical signaling through all Notch receptors, therefore overcoming potential functional redundancies and providing a more comprehensive assessment of Notch signaling contribution in VSM. Through this approach, we have identified a novel role for Notch signaling in the regulation of arterial contractile function through transcriptional control of smooth muscle MLCK. 
EXPERIMENTAL PROCEDURES
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aortic smooth muscle cells (18) .
All mice including the parental SM22-Cre + and conditional DNMAML1 lines were maintained on a C57Bl/6 genetic background.
Cell Culture and Transfections-C3H10T1/2 (10T1/2) myofibroblasts and A10 rat aortic smooth muscle cells (ATCC) were maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (HyClone). Transient plasmid transfections were performed using Xtremegene transfection reagent (Roche Applied Science) with a 3:1 Xtremegene/DNA ratio and cells collected after 48 hours. Cultured primary aortic SMCs from control and mutant mice were isolated and propagated as described previously (18) . Where indicated, cultured aortic SMCs were depolarized with 60 mM KCl for up to 30 min.
Isometric Tension Measurement-Adult mice (10-12 weeks-old) were euthanized by CO2 inhalation. Segments of thoracic aorta (TA), femoral artery (FA) and mesenteric artery (MA) were dissected, cut into 2-3 mm rings, and suspended in an isometric tension myograph (Model 610M, Danish Myo Technology, Aarhus, Denmark) chamber containing PSS buffer (in mmol/L): 112.0 NaCl, 25.7 NaHCO 3 , 4.9 KCl, 2.0 CaCl 2 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 11.5 glucose, and 10.0 Hepes (pH 7.4) equilibrated with gas of 95% O 2 , 5% CO 2 at 37°C as previously described (19) . All chemicals were purchased from Sigma (St. Louis, MO) unless otherwise specified. The resting tension-internal circumference (IC) relation was determined for each FA and MA segment (20) . IC was set to 0.9 Å~ IC 100 , where IC 100 is the internal circumference of the vessel under an effective transmural pressure of 100 mmHg (13.3 kPa). For TA rings, baseline tension in PSS was preset at 4 mN prior to force induction. Cumulative dose-response curves to phenylephrine (PE, an α-adrenergic receptor agonist; 1 nmol/L -10 µmol/L), acetylcholine (ACh, muscarinic receptor agonist; 10 nmol/L -10 µmol/L), sodium nitroprusside (SNP, direct NO donor; 10 nmol/L -10 µmol/L), were generated in the absence or presence of 100 µmol/L L-nitroarginine-methyl ester (L-NAME, competitive antagonist of Larginine/NO production). Dose response curves were performed with single agents and repeated in triplicate at each concentration. For depolarization-induced contractility studies, 60 mmol/L KCl was added to the reaction bath after vessel equilibration in PSS. Treatment regimens are described in each figure legend. Data are presented as active tension (mN) for agonistinduced contraction and percentage of maximum PE-induced tension for ACh and SNP-mediated relaxation.
Calcium Permeabilization and Force Generation Studies-Arteries were permeabilized and force-calcium relationships determined as previously described with minor modifications (21) . In brief, isolated TA and MA segments were mounted in the wire myograph and incubated in high relaxing (HR) solution for 10-20 min and permeabilized with 1000 U/ml α-toxin (Calbiochem, San Diego, CA) in HR for 1 hour at room temperature. The HR solution (pCa >9) was composed of (in mmol/L): 53. concentration between pCa 9 and 4.5 were achieved by mixing appropriate volumes of HR and pCa 4.5 solutions based on the Bathe algorithm. All solutions contained the protease inhibitors leupeptin (1 µg/ml), pepstatin A (2.5 µg/ml), and PMSF (50 µmol/L). The pCa-tension relationship was then determined by bathing the permeabilized vessels in solutions of sequentially increasing Ca 2+ concentrations, ranging from pCa 8.5 to 4.5, while recording active tension for approximately 5 min in each solution or until stabilized.
Blood Pressure Measurements-Adult mice (8-12 weeks-old) were anesthetized with tribromoethanol (Avertin, 0.25 mg/g BW, i.p.) and secured in the supine position. The right internal jugular vein was surgically exposed and canulated for drug infusions. Following calibration, a 1F pressure catheter (SPR-1000, Millar Instruments) was inserted into the left common carotid artery and advanced toward the heart until a stable aortic pressure waveform was observed (PowerLab data acquisition unit, ADInstruments). Heart rates were simultaneously measured through needle electrodes and bio-amplification under separate channel. Animals received escalating doses of either PE (5, 20 , and 100 µg/kg) or AngII (0.05, 0.5 and 5 µg/kg). Each bolus injection delivered a total volume of 30 µl (adjusted to effective concentration) and performed in triplicate, with return to baseline blood pressure prior to each injection. Hemodynamic data analyses were performed using LabChart software (ADInstruments). Data is displayed as absolute change from baseline in mean arterial blood pleasure (MAP, in mmHg). MAP was calculated as the sum of the area under the aortic pressure curve averaged over minimum 100 cardiac cycles. Where indicated, mice were administered N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-S phenylglycine t-Butyl Ester (DAPT, 10 mg/kg s.c.; Calbiochem) or vehicle (DMSO) daily for six days followed by PE dose response measurements.
Cardiac Function Analyses-Mice (8-12 weeks-old) were anesthetized with Avertin (0.25 mg/g BW, i.p.) and transthoracic echocardiography was performed using the Vevo 770 High Resolution Imaging System (Visual Sonics, Canada) equipped with a RMV-707B 30 MHz probe. Standard M-mode sampling was taken through the LV short axis at the midpapillary level before, and 1 min after, phenylephrine (PE) treatment via tail vein injection. A 30 µl bolus volume was maintained for each PE dose.
Immunohistochemistry-Tissues were fixed with 4% paraformaldehyde in PBS at 4°C overnight and cryoprotected with 15% sucrose. Transverse sections (10 mm) were cut using a cryostat (Leica CM3050), washed with PBS and blocked in 1% BSA for 1 hr at room temperature (RT). Serial sections were incubated at 4°C overnight with primary antibodies against SM-MHC (1:100; Abcam), αSMA (1:100; Sigma), cleaved Notch1 (1:100; Cell Signaling) or Jagged-1 (1:100, Santa Cruz) in PBS containing 0.1% Triton X-100 (PBS-TX). Sections were washed in PBS and incubated with anti-rabbit IgG conjugated to DyLight 594 (1:200; Jackson ImmunoResearch, West Grove, PA) or anti-mouse IgG conjugated to Cy3 (1:200; Sigma) diluted in PBS-TX for 1 hr at RT. Sections incubated as described above but without the primary antibodies served as negative controls. Sections were mounted with DAPI (Dako), viewed and images captured by high resolution fluorescence microscopy.
Western Blotting-Arterial segments were quickly dissected, snap-frozen in liquid nitrogen and homogenized in RIPA buffer (50mM Tris-cl pH 7.4, 150mM NaCl, 1% NP40, 0.25% Nadeoxycholate, 1mM PMSF) containing protease inhibitors (Roche Applied Science, Indianapolis, IN) and phosphatase inhibitor (Pierce, Rockford, IL). Alternatively, primary aortic SMCs from control and mutant mice were isolated and total protein lysates collected as described previously (22) . Protein concentrations were determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA).
Western blotting was performed as described previously (23) . Briefly, proteins were transferred to nitrocellulose membranes by standard semi-dry methods (Bio-Rad Laboratories, Hercules, CA). The membranes were incubated for 1 hr at RT with blocking buffer, then with antibodies against MLCK (mouse monoclonal, Sigma, 1:10,000), MLC (rabbit polyclonal, Cell Signaling; 1: 1000), p-MLC (rabbit polyclonal, Cell Signaling, 1:1,000 (24)), αSMA (mouse monoclonal, Sigma, 1:200), SM-MHC (rabbit polyclonal, Abcam, 1:1,000), cleaved Notch1 (rabbit polyclonal, Cell Signaling, 1:1000) or β -actin (rabbit polyclonal, Sigma, 1:1,000) in blocking solution overnight at 4°C. Thereafter, secondary antibodies included horseradish peroxidase (HRP)-conjugated anti-mouse IgG for MLCK and αSMA (Cell Signaling, 1:5,000) and HRP conjugated anti-rabbit IgG for MLC, p-MLC, SM-MHC, cleaved Notch1 and β -actin (Cell Signaling, 1:10,000). Proteins were detected by enhanced chemiluminescence according to the manufacturer's instructions (Cell Signaling) and films were digitally scanned for protein quantification using NIH Image software. Relative densitometric units for MLCK, SM-MHC and αSMA were calculated by normalization to β-actin, while p-MLC was normalized to total MLC. Frozen segments were homogenized in RIPA lysis buffer using TissueLyser II (30 fq1/s, 2 min/s; Qiagen) for 2 cycles. Lysates were centrifuged at 10,000 × g for 10 min at 4ºC, and the supernatants were collected for Western blot detection of phosphorylated and total MLC as described above.
Depolarization and Agonist Treatment of Isolated Aortic Ring Explants
Real-time PCR (qPCR) Analysis of MLCK mRNA-From whole tissue, arterial segments were quickly dissected and snap-frozen in liquid nitrogen and homogenized in Trizol reagent (Invitrogen) followed by standard RNA extraction. Total RNA was also isolated from A10 and primary aortic SMCs collected in Trizol. Two micrograms of total RNA served as template for oligo (dT)-primed reverse transcription using SuperScript III Reverse Transcriptase (Invitrogen). Real-time PCR analyses were performed on a StepOnePlus QPCR system (Applied Biosystems) using mouse MLCK primers previously reported (25) . MLCK primers for A10 derived transcripts included 5'-GACGTGTTCACCCTGGTTCT-3' (forward) and 5'-TTTGTGCAGCATCAGTGACA-3' (reverse). Primers for HRT1 and HRT2 have been described previously (26) . The PCR reaction included 50 ng cDNA reaction, 150 nmol/L forward and reverse MLCK primers and 1X SYBR Green (Applied Biosystems). GAPDH amplification served as the reference gene. Reactions were performed in triplicate and data analyzed according to the method, 2
Luciferase Reporter Studies and Sitedirected Mutagenesis-Luciferase reporter assays were performed in 10T1/2 cells (ATCC) as described previously (26) . Briefly, cells were seeded in 24-well tissue culture plates and cotransfected using Xtremegene transfection reagent (Roche) with 25 ng of p6476 or p389 MLCK luciferase reporter constructs (kind gift of Dr. Paul Herring, Indiana University) and expression plasmids for intracellular Notch1 (ICN1) and DNMAML1 at the indicated ratios (15, 26) . As previously described, plasmid p6476 contains nucleotides -6476 through +115 of the MLCK promoter and p389 is a truncated promoter containing nucleotides -389 through +115 (see Fig. 7 schematic) (15) . Both p6476 and p389 contain a CArG element required for SRF/myocardin-induced transcription, and therefore inclusion of a myocardin expression plasmid in these experiments served as a positive control for activation of the promoter/reporter (26) . Cells were harvested 48 hours after plasmid transfection for measurement of luciferase activity (Promega) using a Veritas plate reader (Turner BioSystems) and normalized to total protein. Experiments were repeated in triplicate. For promoter mutagenesis studies, p6476 was used as the template for a single nucleotide substitution at a core CSL (CC) sequence located at position -3685 (G-to-A). Mutagenesis primers included 5' -GGAATGAGGGACCTGAGAATTCATGCTGG TC-3' (2FCSLf) and 5' -GACCAGCATGAATTCTCAGGTCCCTCATTC C-3' (2FCSLr) and the procedure was performed using a Quickchange II Site Directed Mutagenesis kit (Agilent Technologies) according to manufacturer's instruction.
Two independent mutant clones (p2FCSL2 and p2FCSL5) were confirmed by DNA sequencing and subjected to luciferase assay as above.
Notch Ligand Stimulation Assay-Notch signaling was induced in control SM22-Cre -/DNMAML1 + aortic SMCs cultured in dishes displaying immobilized Jagged1 ligand (Fc-Jag1) as described previously (26) .
Chromatin Immunoprecipitation (ChIP)-Experiments were performed according to the ChIP Assay kit protocol (Millipore). Briefly, following indicated plasmid transfection (for 10T1/2 or A10) or Fc-Jag1 treatment (for primary aortic SMCs), cells were fixed by addition of formaldehyde (1%) to the culture medium for 10 min at 37°C, washed in PBS, scraped and resuspended in lysis buffer for 10 min at 4°C. DNA was sheared to ~500 bp fragments using a Bioruptor apparatus. A fixed volume of lysate was removed as DNA input control and the remaining suspension diluted 10-fold with dilution buffer and further pre-cleared with Protein A agarose/Salmon sperm DNA slurry. Recovered supernatants were incubated with 2 µg Notch 1 antibody (sc-6014, Santa Cruz Biotechnology) or rabbit IgG overnight at 4°C. Immuno-precipitated complexes were collected by pull-down with Protein A agarose/Salmon sperm DNA. The precipitates were extensively washed and incubated in elution buffer. Cross-linking of protein-DNA complexes was reversed and DNA recovered by phenol/chloroform extraction and ethanol precipitation.
Both input and immunprecipitated DNAs were subjected to PCR using primers 5' -TTTGACCTCCATCAGATGGTC-3' (forward) and 5' -AACTTTCCACTGACTTGCTCC-3' (reverse) encompassing the putative -3687 CSL binding site in the MLCK promoter.
Statistical Analysis-All data are presented as mean±SEM.
Significance of differences between groups was determined by analysis of variance (ANOVA) or by Student's t-test. A probability value of <0.05 was considered statistically significant.
RESULTS
SM22-Cre + /DNMAML1 + Mice Exhibit Blunted Pressor Responses to Vasoconstrictors.
Anesthetized control and Notch signaling-deficient (SM22-Cre + /DNMAML1 + ) mice were subjected to continuous intra-arterial blood pressure recording while exposed to escalating concentrations of vasoconstrictors. Baseline heart rate and blood pressure were similar between cohorts (Table 1) . However, in mutant mice, the pressor response to bolus intra-vascular injection of phenylephrine (PE) or angiotensin II (Ang II) was blunted at all concentrations tested and achieved only 55% and 67% of control increment at maximal doses of PE (100 µg/kg) and Ang II (5 µg/kg), respectively (Fig. 1, A and B) . Expression of the SM22-Cre recombinase, alone, did not influence blood pressure responses (Fig. 1C) . We also assessed pressor responses in control mice pre-treated with the non-tissue specific pharmacological Notch signaling inhibitor, DAPT, and determined a significantly blunted blood pressure response with maximal PE (100 µg/kg) (Fig. 1D) . Finally, we interrogated cardiac performance by transthoracic echocardiography, revealing similar functional indices between cohorts both at baseline and with PE treatment (Table 2) . Therefore, inhibition of canonical Notch signaling either through elaboration of DNMAML1 or by DAPT suggested the possibility of intrinsic deficiencies in vascular smooth muscle contractile capacity.
Inhibition of VSM Notch Signaling Impairs Arterial Vessel Contractile Function. To determine if the blunted pressor responses observed in mutant mice reflect altered vascular function, we investigated contractile function of arteries derived from SM22-Cre + /DNMAML1 + and littermate control mice using wire myography. Mutant thoracic aorta (TA) and femoral artery (FA) rings produced significantly less force in response to the α-agonist PE (Fig. 2 , A and D, respectively). This difference in force production remained when rings were pre-treated with Lnitroarginine-methyl ester (L-NAME, 100 µmol/L) to block nitric oxide synthesis (Fig. 2, B and E).
The dose-response of the mutant arteries to a second contractile agonist, Ang II, was also significantly decreased though not to the same magnitude (Fig. 2, C and F) . We next examined contractile function in a representative resistance vessel, the 3rd-order mesenteric artery (MA), more relevant to the control of blood pressure as compared to the larger arteries studied above. The mutant MA rings produced significantly less force in response to PE at the highest concentration (10 -5 mol/L) of the dose-response curve (Fig. 2G ).
To determine if the defect in agonistinduced force production of the mutant arteries may be due to an intrinsic defect in the VSM, vessels were activated by KCl (60 mM)-induced depolarization. Mutant TA, FA and MA rings achieved only 38%, 20%, and 65%, respectively, of the force of control arterial rings (Fig. 3A) . To determine if the defect in force production of the mutant arteries resided at the level of the myofilaments, vessels were permeabilized and calcium-force relationships determined. Both mutant TA and MA produced less force at maximal (pCa 4.5) and sub-maximal (pCa 5.5) calcium concentrations as compared to the control arteries (Fig. 3B) .
Thus, Notch signaling deficiency in VSM causes a defect in contractile responses to agonists and depolarization that at least in part results from reduced calcium activation of force production by the myofilaments.
Inhibition of VSM Notch Signaling Impairs Arterial Relaxation. To determine if the defect in VSM force production was accompanied by impairment in relaxation, arterial rings were treated with acetylcholine (ACh, an endothelialdependent vasorelaxant) or sodium nitroprusside (SNP, an endothelial-independent vasorelaxant). Vascular rings were pre-contracted with submaximal (10 -5 mol/L) PE followed by doseresponse studies of ACh and SNP. Compared to control rings, both mutant FA and MA vessels exhibited significantly reduced relaxation responses to either ACh or SNP (Fig. 4) . This differential response was more pronounced in the MA, including at the highest dose (10 -5 mol/L) of ACh and SNP (Fig. 4, B and D) . Thus, Notch signaling deficiency in VSM causes a defect in relaxant responses to a direct vasodilator again implicating a defect in regulation of force production at the level of the myofilaments.
Notch Signaling-deficient Vessels and Aortic Smooth Muscle Cells Exhibit Dysregulation of Select Contractile Proteins.
The reduced calcium sensitivity of force production and reduced sensitivity to contractile agonists and antagonists suggested altered expression or activity of contractile regulatory proteins. Indeed, MLCK, the principle kinase responsible for penultimate MLC phosphorylation, was reduced to 38% of control in mutant aorta, and the level of phosphorylated (p-) MLC was likewise reduced to 34% of control (Fig. 5, A and B) . Notably, total MLC (t-MLC) content was unchanged, resulting in a mutant ratio of p-MLC to t-MLC of 52% of control (Fig. 5B, box insert) . Moreover, KCl or Ang II treatment markedly induced p-MLC in control but not mutant aortic ring explants despite similar t-MLC content (Fig. 5C) .
Finally, depolarization of cultured mutant aortic SMCs with 60 mM KCl for up to 30 min. failed to elicit MLC phosphorylation in contrast to control cells (Fig. 5D) , while MLCK protein and transcript levels were unaffected by KCl (data not shown). These studies highlight inefficient production of p-MLC in mutant arterial smooth muscle consistent with reduced MLCK content.
Notably, immunohistochemical staining and Western blot analyses revealed similar αSMA and SM-MHC expression patterns and content in the tunica media in control and mutant aortas and derived SMCs (Fig. 6) ; and there was no difference in cross-sectional area between control and mutant vessels nor in the numbers and thickness of VSM layers within the aortic tunica media (Fig. 6, A-D (Fig. 5E) (Fig. 5F, upper left) . To confirm signaling activation in this assay, we observed the expected induction of the known Notch target gene, HRT2 (Fig. 5F, lower left) . Notably, this method of induced Notch signaling is particularly relevant since expression of Jagged-1 and the identification of cleaved (activated) Notch receptor (N1ICD) are both present in the smooth muscle tunica media of intact aorta (supplemental Fig. 1) .
Second, forced expression of constitutively active Notch1 (ICN1) in the rat A10 aortic SMC line also resulted in a several-fold increase in endogenous MLCK transcripts along with a predictable rise in expression of the Notch target gene, HRT1 (Fig. 5F , right upper and lower, respectively). These observations suggested that the altered expression of MLCK could result from a direct transcriptional effect of intracellular Notch on the MLCK promoter.
To test this hypothesis, we measured the sensitivity of the MLCK promoter to Notch signals using previously described and characterized MLCK promoter constructs containing sequences -6476 to +115 (p6476) or -389 to +115 (p389) driving luciferase expression (kind gift of Dr. Paul Herring; Fig. 7A ) (15) . Cotransfection of p6476 and p389 with a myocardin expression plasmid, previously shown to enhance transcription through the CArG motif at -166, resulted in the expected increase in luciferase activity thereby validating the functionality of these constructs (Fig. 7B, Myoc) . Co-transfection of p6476 with 25 ng and 50 ng of constitutively active Notch1 (ICN1) expression plasmid resulted in a dose-dependent increase in luciferase activity which was abrogated by inclusion of DNMAML1 (Fig. 7B, open bars) . Moreover, substitution of ICN1 with constitutively active Notch3 (ICN3) or Notch4 (ICN4) similarly enhanced luciferase activity that was abolished by DNMAML1 (supplemental Fig. 2) . Importantly, while the truncated p389 promoter was reactive to myocardin, transfection with ICN1 failed to induce luciferase activity (Fig. 7B, black bars) .
Thus the sequence from -389 to -6476 is required for MLCK promoter response to Notch signaling. Analysis of this sequence did not reveal complete consensus CSL binding motifs as defined previously (GTGGGAA) (3, 27) . However, the sequence CTGGGAA (hereafter referred to as core CSL or "CC" element), in which cytosine replaces the initial guanine of the consensus sequence, was identified at position -3687 with 100% conservation amongst multiple mammalian species (UCSC Genome Browser, http://genome.ucsc.edu/; Fig. 7A ). To determine whether this CC element was required for Notch activation of the MLCK promoter, the middle guanine was mutated to adenine on the p6476 reporter template as this is known to disrupt CSL binding (3) . Two independent mutant CC clones (p2FCSL2 and p2FCSL5) containing the identical G-to-A substitution (mCC) were subjected to the luciferase assay. While both clones retained expected reactivity to myocardin, ICN1 failed to activate the mutant constructs (Fig. 7C) .
To determine if the putative CC element at -3687 binds the Notch receptor-containing transcription complex, ChIP assays were performed with an anti-Notch1 antibody (αN1) in three different cellular contexts. First, 10T1/2 cells were co-transfected with a constitutively active ICN1 expression plasmid (pC3-ICN1) and either control vector (pGL2b), p6476, or p2FCSL2 DNAs (Fig. 7D) . With pGL2b alone, αN1 (but not αIgG) recovered the CC element containing DNA, suggesting a Notch1 receptor complex interaction at the endogenous MLCK promoter (Fig. 7D, lanes 1 and 2) . Co-transfection with p6476 led to a striking enrichment of αN1 precipitated DNA containing the wild-type CC element, but no increase was observed with cotransfected p2FCSL2 DNA containing the mutated (mCC) element (Fig. 7D, lanes 4 and 6) . Second, we conducted parallel ChIP experiments in the rat A10 aortic SMC line. Again, αN1, but not αIgG, precipitated the endogenous CC element (Fig. 7E , lane 2 versus 1), with further enrichment from the wild-type promoter plasmid p6476 (Fig. 7E, lane 4  versus 2) but not from the mutated promoter in p2FCSL2 (Fig. 7E, lane 6 versus 4) . Finally, in control SM22-Cre -/DNMAML1 + aortic SMCs propagated on pre-fixed Fc-J1 (Fc-Jagged1 fusion) plates to further induce Notch signaling, Jagged1 stimulation resulted in enriched αN1 precipitation of the conserved CC element in the endogenous MLCK promoter (Fig. 7F, lanes 4 versus 2) .
Taken together, these findings identify a novel Notch signaling-sensitive element in the MLCK promoter, providing a molecular mechanism through which Notch signaling regulates VSM contractile function.
DISCUSSION
The SM22-Cre + /DNMAML1 + model of pan-Notch receptor inhibition in VSM demonstrates a novel role for Notch signaling in the transcriptional control of systemic arterial VSM function.
Prior studies in a murine model of CADASIL syndrome demonstrated altered responses of cerebral and caudal arteries to mechanical (flow and pressure) but not agonistinduced reactivity (10, 28) . Additional examination of Notch3-deficient mice revealed functional perturbations limited to cerebral blood flow autoregulation and vascular tone in tail arteries, but not to other arteries including carotid, pulmonary and aorta (7, 8, 11, 29) . Despite failed mechano-transduction of tensile stress, responses to agonist or Ca 2+ stimulation were preserved in cerebral and tail arteries (8, 29) . Aortic and pulmonary arteries from Notch3-deficient mice displayed normal responses to depolarization and agonist-mediated vasoconstriction (7, 11) . More recently, re-examination of Notch3-deficient mice has uncovered a blood flow-dependent autoregulatory defect in renal afferent arterioles, yet non-renal arterioles from these animals functioned comparably to controls (9) . Interestingly, in those study animals, blood pressure was acutely sensitive to high doses of Ang II but not norepinephrine, yet the basis for this differential response was not clear. Hence,
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several mouse models of Notch3 signaling dysregulation have exposed roles for this receptor primarily in transducing mechanostimulation within a subset of arteries but the molecular mechanism underlying this specificity remains unclear.
An important feature of the aforementioned genetic models is the presence of other Notch receptors in VSM along with unaltered expression of Notch target gene families HEY and HES (29) . In one study, reductions in HEY1 and HES1 appeared limited to cerebral but not aortic SMCs from Notch3-deficient mice (7) . Therefore, Notch signaling in VSM may not be fully suppressed in these models. By abrogating canonical Notch signaling through elaboration of DNMAML1 in VSM, our studies demonstrate a substantially broader role for Notch signaling in regulating the function of systemic arteries. Our data suggest either the sum total of Notch signaling output and/or combined signaling through Notch receptors (in addition to Notch3) influences the molecular and functional status of VSM by compromising select component(s) of the contractile apparatus.
Importantly, force generation of Notch signaling-deficient arterial segments was reduced in response to multiple triggers including agonists, depolarization and calcium. The markedly diminished calcium sensitivity of force production in permeabilized preparations is consistent with decreases in MLCK and its activity as indicated by reduced levels of p-MLC. Lack of force production and p-MLC could also result from increased expression or activity of myosin phosphatase (MP) but in fact MP expression was suprisingly reduced in mutant aorta (data not shown). That MP activity may be reduced in this model is suggested by the blunted response to vasorelaxants. However, constrictor, dilator, and depolarization responses require many genes acting through numerous signaling pathways ultimately converging on the activities of MLCK and MP. These measured observations in the mutant vessels and animals might reflect a reestablished hemodynamic equilibrium triggered by altered MLCK and exemplified by similar baseline blood pressures between cohorts. Further investigation will be necessary to address additional interactions and linkage between Notch signals, MLCK and MP regulation.
Interestingly, we did not identify altered levels of VSM differentiation markers, SM-MHC or αSMA in mutant aortas suggesting a selective influence by Notch signaling on the contractile apparatus in this animal model. In vitro studies have shown that Notch signals can promote the transcriptional activity of these contractile genes through CSL recognition motifs in their promoters, an effect possibly dependent on SRF/myocardin (30, 31) .
In contrast, forced expression of constitutively active Notch1 (ICN1) or Hrt proteins inhibited myocardin-mediated activation of SM-MHC and αSMA in smooth muscle differentiation systems (26, 32) . Therefore, our finding of unaltered myofilament levels and histologically normal tunica media in Notch signaling-deficient TA vessels may seem surprising but likely reflects a dominant role for myocardin in governing SM-MHC and αSMA expression in vivo. Our current studies of the MLCK promoter suggest that its activation by myocardin does not require the Notch-sensitive CC element, but it remains to be determined whether synergism with Notch signaling activation or inhibition is a regulatory feature of MLCK gene expression.
Unlike the characteristic thin-walled and dilated cerebral arteries previously described in SM22-Cre + /DNMAML1 + mice, we did not observe similar abnormalities in aortic wall structure that might explain force generation deficits. Such morphometric differences possibly reflect regional functionality and intrinsic compensatory signals in VSM derived from different developmental lineages. In a preliminary ultrastructural examination of the aorta, subtle increases in intercellular space within the tunica media were apparent, but the significance of this finding remains uncertain (data not shown). For example, cerebral arteries from Notch3-deficient mice feature thin tunica media, and tail arteries display non-cohesive VSM cells associated with poor pressure-induced myogenic responses yet intact agonist reactivity (8, 29) .
In contrast, Arboleda-Velasquez et al. examined a Notch3-deficient murine model that did not yield morphological abnormalities in brain vessels or aorta (7) . Functional studies using their model identified a susceptibility to induced stroke associated with cerebral blood flow abnormalities and a transcriptome array of downregulated contractile genes (including MLCK) specifically in brain but not aortic VSM cells (7) . Finally, VSM in transgenic CADASIL mice featured cytoskeletal abnormalities and disruption of intercellular adhesion associated with defective pressure-induced mechanostimulation, yet preserved agonist-induced contractility (33) . These examples illustrate that abnormal VSM intercellular contacts resultant from altered Notch3 signaling can be associated with impaired myogenic responses but normal agonist-or depolarization-induced force generation.
Similar findings of selective contractile impairment derive from murine models wherein absence of cytoskeletal vimentin or dystrophin protein impairs arterial mechanotransduction but not agonist-triggered responses, and in vimentindeficient airway smooth muscle, defective contractility is not associated with impaired MLCK activity (34) (35) (36) . Finally, studies using specific gap junction inhibitors reported a key role for cell adhesion in myogenic responses but not agonist-induced vasoconstriction while other inhibitors abolished vasoconstrictor responses yet preserved depolarization-induced reactivity (37) (38) (39) . Together, these studies highlight the complex relationships existent between VSM cell adhesion, cytoskeletal filaments and signals regulating MLC phosphorylation and myosin activity.
In conclusion, we find that canonical Notch signaling, through the transcriptional control of key regulatory contractile proteins, is required for the contractile function of mature arterial VSM. However, our data do not exclude the existence of additional transcriptionindependent mechanisms through which Notch might regulate MLCK, and such possibilities will require further exploration. It is noteworthy that the clinical efficacy of gamma (γ)-secretase inhibition (pan-Notch receptor inhibition) for treatment of diverse diseases including select malignancies and Alzheimer's dementia is under active investigation (40) (41) (42) . Our current study suggests that such therapies could impact vascular function if sufficient inhibition of Notch signaling occurs within the VSM compartment. Alternatively, pharmacological or genetic manipulation of VSM Notch signaling may be a useful and novel strategy for modulating arterial reactivity. 
FIGURE 2. Inhibition of Notch signaling in VSM impairs agonist-induced contractility. A-B, D-E, G,
Dose response curves for PE-treated vessels. PE was applied to control (Cre -) and mutant (Cre + ) segments of thoracic aorta (A), femoral artery (D), and mesenteric artery (G). L-NAME (LN) pretreatment was included in B and E, respectively. C and F, Dose response curves for Ang II-treated thoracic aorta and femoral arteries, respectively. Generated tension was consistently reduced in mutant vessels. Data is displayed as active tension relative to baseline (PSS only). Measurements were repeated in triplicate at each dose. Each data set represents mean±SEM, n=3 control and 3 mutant. *P<0.02 vs control. 
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